Goldman Sachs Group began coverage on shares of Harmony Biosciences (NASDAQ:HRMY) in a report issued on Sunday morning, Benzinga reports. The firm issued a neutral rating and a $43.00 price objective on the stock.

HRMY opened at $36.48 on Friday. Harmony Biosciences has a 52 week low of $31.88 and a 52 week high of $47.37.

In other news, major shareholder Holdings A/S Novo purchased 132,503 shares of the stock in a transaction dated Friday, August 21st. The stock was acquired at an average cost of $24.00 per share, for a total transaction of $3,180,072.00. Following the completion of the transaction, the insider now directly owns 4,277,300 shares in the company, valued at approximately $102,655,200. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jack Nielsen acquired 3,057 shares of Harmony Biosciences stock in a transaction dated Monday, August 24th. The stock was bought at an average price of $34.30 per share, for a total transaction of $104,855.10. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 138,296 shares of company stock valued at $3,380,687.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc was formerly known as Harmony Biosciences II, Inc and changed its name to Harmony Biosciences Holdings, Inc in February 2020.

Further Reading: How interest rates affect municipal bond prices

Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with's FREE daily email newsletter.